Pulling SEC filings + quote and writing the call…
| Fiscal year | FY2016 | FY2017 | FY2018 | FY2019 | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $553M | $595M | $644M | $644M | $704M | $799M | $942M | $922M | $954M | $1.04B |
| Revenue growth | — | 7.5% | 8.2% | 0.0% | 9.3% | 13.6% | 17.9% | -2.1% | 3.4% | 8.8% |
| Gross profit | $181M | $189M | $204M | $211M | $224M | $243M | $280M | $302M | $336M | $371M |
| Gross margin | 32.7% | 31.8% | 31.7% | 32.8% | 31.8% | 30.4% | 29.8% | 32.7% | 35.3% | 35.7% |
| Operating income | $90.8M | $96.9M | $107M | $103M | $111M | $128M | $145M | $159M | $183M | $209M |
| Operating margin | 16.4% | 16.3% | 16.6% | 15.9% | 15.8% | 16.0% | 15.4% | 17.3% | 19.2% | 20.2% |
| Net income | $56.0M | $90.1M | $78.6M | $79.7M | $84.6M | $96.1M | $105M | $109M | $128M | $155M |
| Net margin | 10.1% | 15.1% | 12.2% | 12.4% | 12.0% | 12.0% | 11.2% | 11.8% | 13.5% | 14.9% |
| EPS (diluted) | $1.75 | $2.79 | $2.42 | $2.45 | $2.60 | $2.94 | $3.25 | $3.35 | $3.93 | $4.75 |
| Fiscal year | FY2016 | FY2017 | FY2018 | FY2019 | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|---|---|---|---|---|
| Operating cash flow | $108M | $111M | $119M | $124M | $150M | $161M | $139M | $184M | $182M | $217M |
| Capital expenditures | $23.0M | $27.5M | $19.2M | $25.8M | $32.1M | $36.1M | $49.1M | — | — | — |
| Free cash flow | $84.6M | $83.1M | $99.5M | $98.7M | $118M | $124M | $89.5M | — | — | — |
| Share buybacks | $1.59M | $1.91M | $1.39M | $21.3M | $13.5M | $35.2M | $35.4M | $4.47M | $5.68M | $108M |
| Dividends paid | $10.7M | $12.1M | $13.4M | $15.1M | $16.7M | $18.7M | $20.7M | $22.9M | $25.6M | $28.3M |
| Fiscal year | FY2016 | FY2017 | FY2018 | FY2019 | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|---|---|---|---|---|
| Cash & equivalents | $38.6M | $40.4M | $54.3M | $65.7M | $84.6M | $103M | $66.6M | $64.4M | $49.5M | $74.6M |
| Total assets | $949M | $964M | $981M | $1.16B | $1.17B | $1.20B | $1.62B | $1.60B | $1.58B | $1.69B |
| Total liabilities | $428M | $347M | $290M | $412M | $338M | $322M | $686M | $543M | $425M | $429M |
| Long-term debt | $226M | $0.00 | $156M | — | — | — | — | — | — | — |
| Shareholders' equity | $521M | $617M | $692M | $744M | $828M | $877M | $938M | $1.05B | $1.15B | $1.26B |
| Retained earnings | $388M | $465M | $528M | $591M | $657M | $732M | $814M | $897M | $997M | $1.12B |
| Shares (wtd avg diluted) | 31.9M | 32.2M | 32.4M | 32.5M | 32.5M | 32.7M | 32.4M | 32.4M | 32.7M | 32.6M |
Every figure is extracted from BALCHEM CORP’s annual reports as filed with the SEC (XBRL company facts) — no third-party estimates. Fiscal years are labeled by period end; filers occasionally re-tag concepts, so a sparse cell means the company didn’t report that concept for that year. Free cash flow = operating cash flow − capital expenditures.
Research and education only — not financial advice. TENKis not a registered investment adviser or broker-dealer and gives no personalized advice. Every call is impersonal — identical for all users, generated on a schedule from SEC filings plus a delayed/third-party price feed — may be wrong or out of date, and is not a recommendation to buy or sell any security. The operator and an affiliated trading operation may hold or trade the securities TENK rates; see Disclosures. Past performance does not guarantee future results. Do your own research.